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OBJECTIVES We report 16 infants with complete congenital heart block (CHB) who developed late-onset
dilated cardiomyopathy despite early institution of cardiac pacing.
BACKGROUND Isolated CHB has an excellent prognosis following pacemaker implantation. Most early
deaths result from delayed initiation of pacing therapy or hemodynamic abnormalities
associated with congenital heart defects.
METHODS A multi-institutional study was performed to identify common clinical features and possible
risk factors associated with late-onset dilated cardiomyopathy in patients born with congenital
CHB.
RESULTS Congenital heart block was diagnosed in utero in 12 patients and at birth in four patients. Ten
of 16 patients had serologic findings consistent with neonatal lupus syndrome (NLS). A
pericardial effusion was evident on fetal ultrasound in six patients. In utero determination of
left ventricular (LV) function was normal in all. Following birth, one infant exhibited a rash
consistent with NLS and two had elevated hepatic transaminases and transient thrombocy-
topenia. In the early postnatal period, LV function was normal in 15 patients (shortening
fraction [SF] 5 34 6 7%) and was decreased in one (SF 5 20%). A cardiac pacemaker was
implanted during the first two weeks of life in 15 patients and at seven months in one patient.
Left ventricular function significantly decreased during follow-up (14 days to 9.3 years, SF 5
9% 6 5%). Twelve of 16 patients developed congestive heart failure before age 24 months.
Myocardial biopsy revealed hypertrophy in 11 patients, interstitial fibrosis in 11 patients, and
myocyte degeneration in two patients. Clinical status during follow-up was guarded: four
patients died from congestive heart failure; seven required cardiac transplantation; one was
awaiting cardiac transplantation; and four exhibited recovery of SF (31 6 2%).
CONCLUSIONS Despite early institution of cardiac pacing, some infants with CHB develop LV cardiomy-
opathy. Patients with CHB require close follow-up not only of their cardiac rate and rhythm,
but also ventricular function. (J Am Coll Cardiol 2001;37:238–42) © 2001 by the American
College of Cardiology
The incidence of congenital heart block (CHB) in the
general population has been estimated to vary between
1/15,000 and 1/22,000 live-born infants (1). Heart block
may be associated with maternal autoantibodies against
SSA (Ro) or SSB (La) proteins (neonatal lupus syndrome,
NLS) or secondary to specific cardiac malformations, e.g.,
atrioventricular (AV) discordance or polysplenia with AV
canal defect. Heart block resulting from the NLS is most
often identified between 18 and 28 weeks gestational age
and is frequently permanent (2). Isolated CHB has an
excellent prognosis following pacemaker implantation (3–
5). In most series of patients with CHB, early death results
from delayed initiation of pacing therapy or hemodynamic
compromise from associated significant congenital heart
disease.
Waltuck and Buyon (2) have assessed fetal and neonatal
outcome in 55 children known to be autoantibody positive
for SSA (Ro) or SSB (La) antigen. Seventeen, or 31%, of
the children died during follow-up. Deaths were classified
as either early or late. Early deaths occurred in the first
month and were attributed to congestive heart failure (four
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patients), multiorgan failure (three patients), respiratory
failure (two patients), stillbirth with CHB (one patient),
and unknown causes (two patients). The causes of late death
were congestive heart failure (three patients), pacemaker
failure (one patient), and complications of pacemaker im-
plantation (one patient).
Our purpose is to describe the clinical course of 16 infants
with CHB who developed late-onset dilated congestive
cardiomyopathy despite early institution of cardiac pacing.
A multi-institutional study was performed to identify com-
mon clinical features and possible risk factors associated
with late-onset dilated cardiomyopathy in patients born
with congenital complete AV block.
METHODS
This study was a retrospective collaborative effort among ten
pediatric cardiology institutions involved in the care of
infants with congenital CHB who developed cardiomyop-
athy despite early implantation of a cardiac pacemaker. The
participating centers and the number of contributed patients
are as follows: Children’s National Medical Center, Wash-
ington, DC (four patients); Medical College of South
Carolina, Charleston, South Carolina (three patients); Wil-
helmina Children’s Hospital, Utrecht, Netherlands (two
patients); Children’s Hospital and Medical Center, Seattle,
Washington (one patient); Children’s Hospital of the
King’s Daughters, Norfolk, Virginia (one patient); Geis-
inger Clinic, Danville, Pennsylvania (one patient); Poly-
clinic Medical Center, Harrisburg, Pennsylvania (one pa-
tient); Rainbow Babies and Children’s Hospital, Cleveland,
Ohio (one patient); Texas Children’s Hospital, Houston,
Texas (one patient); and Yale-New Haven Medical Center,
New Haven, Connecticut (one patient). A questionnaire
addressing the patients’ clinical course and follow-up was
given to each center to complete.
Standard methods for calculation of the echocardio-
graphic shortening fraction (SF) were used (left ventricular
end-diastolic dimension—left ventricular systolic dimen-
sion/left ventricular end-diastolic dimension). Numerical
results are expressed in the text as the mean 6 SD.
RESULTS
In Utero Course
Congenital heart block was diagnosed in utero in 12 infants.
The mean gestational age of clinical presentation was
26.3 6 6.3 weeks, age range 18 to 37 weeks. Nine fetuses
were female and three were male. A pericardial effusion was
visualized on fetal ultrasound in six of 12 fetuses. Left
ventricular function was normal in all. Four patients re-
ceived medical therapy in utero: dexamethasone (two pa-
tients), terbutaline (one patient), and betamethasone (one
patient). In none did the degree of AV block improve.
Pericardial effusion improved or resolved in two of two
patients with preexisting effusions. The heart rate in utero
averaged 49 6 7 beats/min (Table 1).
At the time of diagnosis of CHB, 13 mothers were
asymptomatic, one had Sjogren’s syndrome, and two had
systemic lupus erythematosus.
Perinatal Period
A detailed clinical and laboratory evaluation of each infant
was performed postnatally. A rash consistent with neonatal
lupus was detected in one newborn. Two neonates had
Abbreviations and Acronyms
AV 5 atrioventricular
CHB 5 congenital heart block
NLS 5 neonatal lupus syndrome
SF 5 shortening fraction
Table 1. Presence of Heart Disease and Cardiac Function
Patient Presence of CHD Age at CHF SF: Birth SF: Worst SF: Follow-up Outcome
1 None Day: 14 0.27 0.18 — Died
2 None Month: 6 0.31 0.10 0.29 Alive
3 None Month: 11 0.34 0.15 0.25 Alive
4 Small PDA/PFO Month: 12 0.38 0.10 — Died
5 Small VSD/PDA Month: 2 0.20 0.11 — TX
6 ASD, s/p closure Month: 11 0.30 0.05 0.34 Alive
7 Small PDA/PFO, s/p
PDA ligation
Month: 30 0.30 0.05 — TX
8 None Month: 10 0.27 0.18 — TX
9 Small PDA/PFO Month: 14 0.30 0.10 0.35 Alive
10 Pulmonary stenosis Month: 21 0.30 0.02 — TX
11 None Month: 4 0.54 0.05 — TX
12 Small PDA Month: 20 0.45 0.14 — TX
13 None Year: 9.3 0.31 0.05 — TX
14 None Year: 4.4 0.32 0.06 0.06 TX list
15 None Month: 9 0.40 0.11 — Died
16 None Year: 3.8 0.32 0.06 — Died
ASD 5 atrial septal defect; CHD 5 congenital heart disease; EFE 5 endocardial fibroelastosis; PDA 5 patent ductus arteriosus; PFO 5 patent foramen ovale; SF 5 shortening
fraction; TX 5 cardiac transplantation.
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mildly elevated hepatic transaminases and thrombocytope-
nia. Congenital heart disease was evident in seven infants:
patent foramen ovale/small atrial septal defect with a small
patent ductus arteriosus (three patients), a tiny ventricular
septal defect and small patent ductus arteriosus (one pa-
tient), an atrial septal defect requiring surgical closure (one
patient), a moderate to large sized patent arteriosus requir-
ing surgical ligation (one patient), and pulmonary valve
stenosis requiring balloon angioplasty (one patient).
Left ventricular function was assessed by 2D echo and
was found to be normal in 15 newborns (Table 1). The
average SF was 34 6 7%. Left ventricular function was
decreased in one patient. The SF in this infant was 20%.
Because of concern over slow heart rates, a cardiac
pacemaker was implanted in all 16 patients (Table 1).
Pacemaker implantation occurred on day of life 1 (eight
patients), day of life 2 (two patients), day of life 3 (one patient),
day of life 4 (two patients), day of life 7 (one patient), day of life
10 (one patient) and at seven months (one patient). The
mode of pacing was dual chamber in ten patients and single
chamber (VVIR) in six patients (Table 2).
The heart rate prior to pacemaker implantation was 51 6
6 beats/min (Table 2). Following pacemaker implantation,
the heart averaged 121 6 23 beats/min. The rhythm was
predominantly atrial sensed-ventricular paced in those pa-
tients with dual-chamber pacemakers. The ventricular pac-
ing lead was placed near the inferior right ventricle in 14 of
16 patients. In two patients the ventricular pacing lead was
placed on the left ventricle.
Serologic findings of infants with CHB. Ten of 16
patients had serologic findings consistent with NLS, anti-
SSA (Ro) antibody was positive in seven infants and
anti-SSB (La) antibody was detected in five newborns.
Serologic findings were negative in three patients and
unknown in three patients. No consistent immunoblot
pattern of antibody profile was evident. Anti-48 KD (SSB/
La) antibody was observed in four of five patients tested,
anti-52 KD (SSA/Ro) antibody was noted in five of five
patients, and anti-60 KD (SSA/Ro)-antibody was found in
five of five tested specimens.
Postnatal clinical course. Thirteen infants developed
symptoms of congestive heart failure between two weeks
and 30 months of age, mean age 5 11.6 6 8.3 months,
associated with depressed left ventricular function. At the
time of clinical presentation, nine infants had symptoms or
signs of an upper respiratory tract infection, two with otitis
media. One infant had a respiratory syncytial virus infection.
Mean left ventricular shortening fraction was 10 6 5%
(Table 1). All patients were treated with positive inotropic
agents and diuretics. Three patients developed clinical
deterioration of cardiac function slightly later in life (be-
tween 3.75 and 9.3 years, mean age 5.8 6 3.0 years). At the
time of clinical presentation, two of the three older children
presented with symptoms or signs of an upper respiratory
tract (n 5 1) or gastrointestinal infection (n 5 1). Mean left
ventricular shortening fraction was 9 6 5%.
Myocardial biopsy or histologic examination of the ex-
planted heart revealed the following: myocyte hypertrophy
in 11 of 16 patients, interstitial fibrosis in 11 of 16
specimens, and myocyte degeneration in two subjects. Im-
munoflorescent studies for antibody, immune-complex or
complement deposits were unrevealing in seven patients. In
no specimen was an active inflammatory infiltrate detected
(Table 3).
During follow-up, four infants died from congestive heart
failure and low cardiac output. The ages at death were one
month, nine months, 18 months and 4.5 years. Seven
patients required cardiac transplantation. The ages at trans-
plantation ranged from nine months to ten years (mean age
was 37 6 38 months). One patient was awaiting transplan-
tation. Myocardial function recovered in four patients. The
Table 2. Pacemaker Implantation (Age at and Mode of); and Average Heart Rate (BPM) (Prior to and After)











1 Day: 1 DDD 50 55 155 RV: inferior
2 Day: 1 DDD 35 40 130 RV: inferior
3 Day: 1 DDD 55 55 140 RV: inferior
4 Day: 2 DDD 55 55 125 RV: inferior
5 Day: 1 and 10 VVI, DDD 40 45 130 RV: inferior
6 Day: 1 DDD 50 52 140 RV: inferior
7 Month: 7 and 25 VVI, DDD 55 65 125 LV: high lateral
8 Day: 1 VVI 45 45 100 RV: inferior
9 Day: 4 DDD 50 50 120 LV
10 Day: 1 VVI 60 45 120 RV: inferior
11 Day: 3, and Month: 7 VVI, DDD 45 50 160 RV: inferior
12 Day: 1 VVI NA 48 110 RV: inferior
13 Day: 1 DDD NA 58 120 RV: inferior
14 Day: 7 VVI NA 50 100 RV: inferior
15 Day: 2 DDD 50–55 50 80 RV: inferior
16 Day: 4 DDD NA 45–48 80 RV: inferior
DDD 5 dual chamber pacing mode; LV 5 left ventricle; NA 5 not available; PM 5 pacemaker; RV 5 right ventricle; VVI 5 single-chamber ventricular pacing mode.
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recovery shortening fraction in these subjects was 31 6 5%
(Table 1).
Each institution was surveyed as to the number of new
patients presenting each year with congenital complete AV
block (average was between one and two patients/year). The
patients enrolled in this study presented at the participating
institutions between 1984 and 1999. We therefore approx-
imated the incidence of development of dilated cardiomy-
opathy in infants with congenital complete AV block to be
between 5% and 11%.
DISCUSSION
In the modern era, CHB generally has an excellent prog-
nosis. Some patients have survived to their 40’s or even 60’s
without pacing (6,7). In rare isolated cases, AV conduction
has spontaneously returned to sinus rhythm (8,9). Groves et
al. recently reported their experience with the longitudinal
follow-up of 36 fetuses detected in utero with CHB (4).
These authors noted no deaths beyond the neonatal period.
Previous reports of death in early infancy were difficult to
interpret, given that the majority of the deaths were sec-
ondary to congestive heart failure in the setting of brady-
cardia, i.e., most of these patients failed to receive a
pacemaker or may have had coexistent congenital heart
disease. Our study highlights an unusual and rare observa-
tion that has been underappreciated, i.e., the development
of severe cardiomyopathy despite early pacemaker implan-
tation (median age was the first day of life). Two similar
cases had previously been reported (10).
Possible risk factors. The obviously small number of
patients available for study limited the power of our analysis;
however, no consistent finding in the clinical history or
evaluation seemed to predict the development of cardiomy-
opathy. Analysis of serologic findings and the immunoblot
patterns failed to reveal differences that would predict the
development of a cardiomyopathic state. Waltuck et al. (2)
reported similar results in attempting to define specific
immunoblot patterns that distinguished affected versus non-
affected infants (complete AV block) born to anti-SSA (Ro)
or anti-SSB (La) positive mothers.
On histologic evaluation, the presence of hypertrophy
and interstitial fibrosis was noted in either myocardial
biopsy specimens or on the explanted heart. Prior patho-
logic reports have made similar observations. Lev et al. (11)
reported endocardial fibroelastosis and fibrosis in the right
and left ventricle in seven cases. Their findings appeared not
to be restricted to the conduction system but involved
working ventricular myocardium. On rare occasions, scat-
tered foci of mononuclear inflammatory cells were detected.
Litsey et al. (12) observed mild endocardial fibroelastosis in
several areas of the heart, along with widespread dystrophic
calcification. Lee et al. (13) observed IgG and complement
deposition in all cardiac tissues examined, not only in the
myocardium but also in and around the conduction system.
Several other case reports further support the concept of
transient myocarditis that evolves into fibroelastosis (14–
16). At the time of clinical presentation 11 of our 16
patients had an upper respiratory/gastrointestinal infection,
which might have reactivated a previously dormant inflam-
matory process.
Cardiac damage consisting of myocarditis, inflammation,
and fibrosis of the conduction system has similarly been
observed in 60% to 70% of adult patients with polymyositis
associated with antibodies to tissue ribonucleoproteins (17).
Anti-SSA (Ro) antibodies are detected in up to 60% of
these patients.
Sustained rapid ventricular rates, as has been noted
during incessant forms of supraventricular tachycardia, may
elicit a tachycardia-induced cardiomyopathy (18). All of our
infants underwent early pacemaker implantation for “slow”
Table 3. Histologic Findings
Patient Histologic Findings
Myocyte hypertrophy Fibrosis Cellular degeneration Immunofluorescence
1 2 1 2 2
2 1 1 2 2
3 1 2 2 2
4 1 1 2 2
5 1 1 (EFE) 2 ND
6 1 1 2 ND
7 1 1 (EFE) 2 ND
8 2 1 2 ND
9 1 1 1 ND
10 1 1 (EFE) 2 ND
11 1 1 (EFE) 1 ND
12 1 2 2 2
13 2 2 2 2
14 1 1 2 2
15 2 2 2 ND
16 2 2 2 ND
EFE 5 endocardial fibroelastosis; ND 5 not done; 1 present; 2 absent.
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heart rates. Concern may be raised that the increased rate
that followed pacemaker implantation may have provoked a
form of tachycardia-induced cardiomyopathy. Histologic
studies by Karpawich et al. (19,20) in a chronic canine
model of cardiac pacing, as well as in children with
congenital AV block paced from the right ventricular apex,
have revealed dystrophic changes in myocardial structure
that may contribute to a pacing-induced cardiomyopathic
state. We feel that such was not the case in our patient
population, because one-quarter of the patients clinically
improved without any alteration in their pacing mode or
rate. Furthermore, the heart rates after pacemaker implan-
tation were within the normal range for this age group.
Previous studies have assessed the outcome of pediatric
patients with dilated cardiomopathy (21–23). These studies
have revealed that approximately one-third of patients die,
one-third improve clinically but continue with residual
hemodynamic dysfunction and one-third recover com-
pletely. As mentioned earlier, our patient population fol-
lowed a similar trend.
Study limitations. Several limitations to our study need to
be specified. Seven of the 16 patients had congenital heart
defects with three requiring intervention. Either the pres-
ence of the congenital heart disease or the intervention
required for its management might have contributed to the
ventricular dysfunction in these patients. The surgical or
balloon angioplasty techniques required for treatment of the
congenital heart defects have rarely been reported to result
in the degree of ventricular dysfunction experienced by our
patient population. Four patients were paced in the VVIR
mode, which could conceivably have contributed to their
congestive heart failure symptoms. Single-chamber ventric-
ular pacing, although less than ideal, is usually well tolerated
in this age group and is clinically performed at many centers
without adverse outcome.
Conclusions. We conclude that despite early institution of
cardiac pacing, some infants with CHB will develop car-
diomyopathy. Patients with CHB require close follow-up,
not only of their cardiac rate and rhythm, but also of their
ventricular function, particularly during the first few years of
life. Late-onset cardiomyopathy in patients with CHB may
represent a sequela of in utero autoimmune or postnatal
reactivation myocarditis. One must also consider the possi-
bility that early intervention with cardiac pacing may pro-
duce a tachycardia-induced cardiomyopathy.
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